Monitor for shareholder approval and regulatory clearances, as the deal is expected to close in Q3 2026. The significant premium and immediate accretion signal strong confidence in the combined company's growth, making this a key event for Ligand's stock. Watch for updates on the Janssen litigation, as its outcome will determine the value of the CVRs distributed to XOMA shareholders.
Price Chart
Executive Summary
Ligand Pharmaceuticals is acquiring XOMA Royalty in an all-cash transaction valued at approximately $739 million, with XOMA shareholders receiving $39.00 per share plus a contingent value right (CVR) tied to potential litigation proceeds. The deal, unanimously approved by both boards and supported by major shareholders, is expected to close in Q3 2026 and is immediately accretive to Ligand's earnings.
Key Financial Metrics
Key Facts
- Ligand Pharmaceuticals (LGND) is acquiring XOMA Royalty (XOMAP) for $39.00 per share in cash, representing a 14% premium to the 30-day volume-weighted average price.
- The total equity value of the transaction is approximately $739 million.
- XOMA shareholders will also receive one non-transferable Contingent Value Right (CVR) per share, entitling them to 75% of net proceeds from ongoing litigation against Janssen Biotech.
- The deal is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
- Ligand expects the acquisition to be immediately accretive to its 2026 adjusted EPS and accretive by $1.50 per share in 2027.
Financial Impact
Approximately $739 million total equity value. $39.00 per share in cash for XOMA shareholders, plus a CVR for potential future litigation proceeds.
Risk Factors
- The deal is subject to customary closing conditions, including shareholder approval and regulatory clearances, which could delay or prevent completion.
- The value of the CVRs is contingent on the outcome of the Janssen Biotech litigation, which is uncertain and could result in no additional proceeds for XOMA shareholders.
- Integration risks exist, as combining the two royalty portfolios may not yield the anticipated synergies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179085 |
| Document: d139894d8k.htm | 0001193125-26-179085 |
| Document: d139894dex101.htm | 0001193125-26-179085 |
| Document: d139894dex991.htm | 0001193125-26-179085 |
| Document: 0001193125-26-179085-index-headers.html | 0001193125-26-179085 |
| Document: 0001193125-26-179085-index.html | 0001193125-26-179085 |
| Document: 0001193125-26-179085.txt | 0001193125-26-179085 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 16w ago | DEFM14A | $25.51 $24.98 | ▼ −2.07% | ▼ −3.96% | — |
May 26, 2026 18w ago | 425 | $25.36 $25.48 | ▲ +0.47% | ▲ +2.42% | — |
May 18, 2026 19w ago | DEFA14A | $25.38 $25.40 | ▲ +0.08% | ▼ −1.50% | — |
Apr 27, 2026 22w ago | DEFA14A | $25.25 $25.36 | ▲ +0.44% | ▼ −4.52% | — |
Apr 27, 2026 22w ago | 8-K | $25.25 $25.36 | ▲ +0.44% | ▼ −4.52% | — |
Mar 30, 2026 26w ago | DEFA14A | $25.74 $25.62 | ▼ −0.47% | ▼ −9.89% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access